Parkinson's Disease (PD) is the second most common neurodegenerative disorder. Clinical approaches to manage PD include symptomatic therapies, serving to compensate for the effects of dopaminergic neuronal deficits, as well as more recently a move toward disease modification, with the goal of slowing or stopping disease progression. This perspective surveys the approved therapies for PD treatment as well as provides a view of the ongoing clinical approaches aimed at improving outcomes for PD patients.
Keywords: Disease modification; Dopamine; Neurodegeneration; Parkinson’s Disease; Symptomatic; α-Synuclein.
Copyright © 2017 Elsevier Ltd. All rights reserved.